High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): A report from the European Rhabdoid Registry (EU-RHAB)

M. Benesch, K. Bartelheim, G. Fleischhack, B. Gruhn, P. G. Schlegel, O. Witt, K. D. Stachel, H. Hauch, C. Urban, F. Quehenberger, M. Massimino, T. Pietsch, M. Hasselblatt, F. Giangaspero, U. Kordes, R. Schneppenheim, P. Hauser, T. Klingebiel, M. C. Frühwald

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. Nine patients presented with metastatic disease at diagnosis. A partial or subtotal resection was achieved in 11, a total resection in five and a biopsy in three patients. Patients received a median of six chemotherapy cycles prior to HDCT. Additional radiotherapy was performed in 14 patients (first-line, n=9; following progression, n=5). Six patients underwent tandem auto-SCT. Disease status before HDCT was CR in six, PR in eight, stable disease in two and progressive disease (PD) in two patients (data missing, n=1). With a median follow-up of 16 months, 14 patients progressed. Estimated progression-free and OS at 2 years were 29% (±11%) and 50% (±12%), respectively. At last follow-up, eight patients were alive (first CR, n=4; second CR, n=2; PR, n=1; PD, n=1). Eleven patients died of PD. Median time-to-progression was 14 months. Selected patients with AT/RT might benefit from HDCT with radiotherapy. The definitive impact of this treatment modality has to be evaluated prospectively in a randomized trial.

Original languageEnglish
Pages (from-to)370-375
Number of pages6
JournalBone Marrow Transplantation
Volume49
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Registries
Drug Therapy
Atypical Teratoid Tumor
Typical Teratoid Rhabdoid Tumor
Radiotherapy
Biopsy

Keywords

  • Atypical teratoid/rhabdoid tumors
  • auto-SCT
  • children

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT) : A report from the European Rhabdoid Registry (EU-RHAB). / Benesch, M.; Bartelheim, K.; Fleischhack, G.; Gruhn, B.; Schlegel, P. G.; Witt, O.; Stachel, K. D.; Hauch, H.; Urban, C.; Quehenberger, F.; Massimino, M.; Pietsch, T.; Hasselblatt, M.; Giangaspero, F.; Kordes, U.; Schneppenheim, R.; Hauser, P.; Klingebiel, T.; Frühwald, M. C.

In: Bone Marrow Transplantation, Vol. 49, No. 3, 03.2014, p. 370-375.

Research output: Contribution to journalArticle

Benesch, M, Bartelheim, K, Fleischhack, G, Gruhn, B, Schlegel, PG, Witt, O, Stachel, KD, Hauch, H, Urban, C, Quehenberger, F, Massimino, M, Pietsch, T, Hasselblatt, M, Giangaspero, F, Kordes, U, Schneppenheim, R, Hauser, P, Klingebiel, T & Frühwald, MC 2014, 'High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): A report from the European Rhabdoid Registry (EU-RHAB)', Bone Marrow Transplantation, vol. 49, no. 3, pp. 370-375. https://doi.org/10.1038/bmt.2013.208
Benesch, M. ; Bartelheim, K. ; Fleischhack, G. ; Gruhn, B. ; Schlegel, P. G. ; Witt, O. ; Stachel, K. D. ; Hauch, H. ; Urban, C. ; Quehenberger, F. ; Massimino, M. ; Pietsch, T. ; Hasselblatt, M. ; Giangaspero, F. ; Kordes, U. ; Schneppenheim, R. ; Hauser, P. ; Klingebiel, T. ; Frühwald, M. C. / High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT) : A report from the European Rhabdoid Registry (EU-RHAB). In: Bone Marrow Transplantation. 2014 ; Vol. 49, No. 3. pp. 370-375.
@article{d4d8625463a1451d9dd5967104d8517e,
title = "High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): A report from the European Rhabdoid Registry (EU-RHAB)",
abstract = "A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. Nine patients presented with metastatic disease at diagnosis. A partial or subtotal resection was achieved in 11, a total resection in five and a biopsy in three patients. Patients received a median of six chemotherapy cycles prior to HDCT. Additional radiotherapy was performed in 14 patients (first-line, n=9; following progression, n=5). Six patients underwent tandem auto-SCT. Disease status before HDCT was CR in six, PR in eight, stable disease in two and progressive disease (PD) in two patients (data missing, n=1). With a median follow-up of 16 months, 14 patients progressed. Estimated progression-free and OS at 2 years were 29{\%} (±11{\%}) and 50{\%} (±12{\%}), respectively. At last follow-up, eight patients were alive (first CR, n=4; second CR, n=2; PR, n=1; PD, n=1). Eleven patients died of PD. Median time-to-progression was 14 months. Selected patients with AT/RT might benefit from HDCT with radiotherapy. The definitive impact of this treatment modality has to be evaluated prospectively in a randomized trial.",
keywords = "Atypical teratoid/rhabdoid tumors, auto-SCT, children",
author = "M. Benesch and K. Bartelheim and G. Fleischhack and B. Gruhn and Schlegel, {P. G.} and O. Witt and Stachel, {K. D.} and H. Hauch and C. Urban and F. Quehenberger and M. Massimino and T. Pietsch and M. Hasselblatt and F. Giangaspero and U. Kordes and R. Schneppenheim and P. Hauser and T. Klingebiel and Fr{\"u}hwald, {M. C.}",
year = "2014",
month = "3",
doi = "10.1038/bmt.2013.208",
language = "English",
volume = "49",
pages = "370--375",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT)

T2 - A report from the European Rhabdoid Registry (EU-RHAB)

AU - Benesch, M.

AU - Bartelheim, K.

AU - Fleischhack, G.

AU - Gruhn, B.

AU - Schlegel, P. G.

AU - Witt, O.

AU - Stachel, K. D.

AU - Hauch, H.

AU - Urban, C.

AU - Quehenberger, F.

AU - Massimino, M.

AU - Pietsch, T.

AU - Hasselblatt, M.

AU - Giangaspero, F.

AU - Kordes, U.

AU - Schneppenheim, R.

AU - Hauser, P.

AU - Klingebiel, T.

AU - Frühwald, M. C.

PY - 2014/3

Y1 - 2014/3

N2 - A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. Nine patients presented with metastatic disease at diagnosis. A partial or subtotal resection was achieved in 11, a total resection in five and a biopsy in three patients. Patients received a median of six chemotherapy cycles prior to HDCT. Additional radiotherapy was performed in 14 patients (first-line, n=9; following progression, n=5). Six patients underwent tandem auto-SCT. Disease status before HDCT was CR in six, PR in eight, stable disease in two and progressive disease (PD) in two patients (data missing, n=1). With a median follow-up of 16 months, 14 patients progressed. Estimated progression-free and OS at 2 years were 29% (±11%) and 50% (±12%), respectively. At last follow-up, eight patients were alive (first CR, n=4; second CR, n=2; PR, n=1; PD, n=1). Eleven patients died of PD. Median time-to-progression was 14 months. Selected patients with AT/RT might benefit from HDCT with radiotherapy. The definitive impact of this treatment modality has to be evaluated prospectively in a randomized trial.

AB - A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. Nine patients presented with metastatic disease at diagnosis. A partial or subtotal resection was achieved in 11, a total resection in five and a biopsy in three patients. Patients received a median of six chemotherapy cycles prior to HDCT. Additional radiotherapy was performed in 14 patients (first-line, n=9; following progression, n=5). Six patients underwent tandem auto-SCT. Disease status before HDCT was CR in six, PR in eight, stable disease in two and progressive disease (PD) in two patients (data missing, n=1). With a median follow-up of 16 months, 14 patients progressed. Estimated progression-free and OS at 2 years were 29% (±11%) and 50% (±12%), respectively. At last follow-up, eight patients were alive (first CR, n=4; second CR, n=2; PR, n=1; PD, n=1). Eleven patients died of PD. Median time-to-progression was 14 months. Selected patients with AT/RT might benefit from HDCT with radiotherapy. The definitive impact of this treatment modality has to be evaluated prospectively in a randomized trial.

KW - Atypical teratoid/rhabdoid tumors

KW - auto-SCT

KW - children

UR - http://www.scopus.com/inward/record.url?scp=84904243082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904243082&partnerID=8YFLogxK

U2 - 10.1038/bmt.2013.208

DO - 10.1038/bmt.2013.208

M3 - Article

C2 - 24419520

AN - SCOPUS:84904243082

VL - 49

SP - 370

EP - 375

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -